ImmuCell (NASDAQ:ICCC) Releases Quarterly Earnings Results

ImmuCell (NASDAQ:ICCC) issued its earnings results on Thursday, February 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. ImmuCell had a negative return on equity of 0.82% and a negative net margin of 1.61%. The company had revenue of $3.13 million during the quarter.

Shares of ImmuCell (ICCC) traded up $0.10 during trading on Friday, hitting $7.35. 1,032 shares of the stock traded hands, compared to its average volume of 8,119. The stock has a market cap of $37.43, a PE ratio of -245.00 and a beta of 1.03. ImmuCell has a 1-year low of $5.00 and a 1-year high of $9.25. The company has a quick ratio of 0.99, a current ratio of 1.75 and a debt-to-equity ratio of 0.27.

WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://ledgergazette.com/2018/02/17/immucell-iccc-issues-earnings-results.html.

About ImmuCell

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Earnings History for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply